Merck's hep C regimen with Gilead's Sovaldi fails to deliver

November 10, 2014 11:22 AM

12 0

The interim data released by Merck & Co reveals that the company's plan to shorten hepatitis C treatment to just four weeks by adding Sovaldi - manufactured by Gilead Sciences Inc - to its own oral two-drug combination failed to deliver the desired result.

The data from midstage study showed that it happened due to a high rate of relapses.

Also read: Experimental Ebola Treatment May Be Deployed to Congo

Read more

To category page